Barclays analyst Gena Wang raised the firm’s price target on Vir Biotechnology to $28 from $27 and keeps an Overweight rating on the shares. The company announced a strategic prioritization with a workforce cut, says the firm, which would look for near-term data to further validate Vir’s platform and assets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Vir gets FDA clearance, fast track designation for tobevibart and elebsiran
- Biotech Alert: Searches spiking for these stocks today
- Vir Biotechnology price target raised to $15 from $12 at Morgan Stanley
- Vir Biotechnology price target raised to $13 from $12 at JPMorgan
- Vir Biotechnology combo shows ‘unprecedented’ response, says H.C. Wainwright